Home
Resources
Publications
Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

Raymundo Sanchez-Ponce, Li-Quan Wang, Wei Lu, Jana von Hehn, Maryann Cherubini, Roger Rush

Metabolites. 2012 Sep 11;2(3):596-613.

PMID: 24957649

Abstract:

STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric configuration. This metabolite undergoes some further metabolism by glucuronide conjugation. Consequences of this metabolic difference are a lower Cmax and lower early plasma exposure of S-baclofen compared to R-baclofen and marginally lower urinary excretion of S-baclofen after racemic baclofen administration. These differences introduce compound-related exposure variances in humans in which subjects dosed with racemic baclofen are exposed to a prominent metabolite of baclofen whilst subjects dosed with STX209 are not. For potential clinical use, our findings suggest that STX209 has the advantage of being a biologically defined and active enantiomer.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP22518270	Baclofen Related Compound A		22518-27-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: